Comparison of vildagliptin and alogliptin in patient with type 2 diabetes

Comparison of vildagliptin and alogliptin in patient with type 2 diabetes - Comparison of vildagliptin and alogliptin

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005813

Enrollment

Registered

2011-06-20

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Vildagliptin 100mg/day for 3 months alogliptin 20mg/day for 3 monts

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Outpatients who have been taking 50mg of sitagliptin for 1month or monre 2)3)Type 2 diabete mellitus (HbA1c level:more than 6.6%, less than 9.1% 4)Pts with written IC 5)Age more than 20, less than 85

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4) severe renal dysfunction (sCr: more than 1.5mg/dl) 5)Patients who use of insulin 6)regnacy 7)Allergy for vildagliptin or alogliptin 8)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Achievement rate of HbA1c <6.6%	—

Secondary

Measure	Time frame
1) Achievement rate of blood glucose <130mg/dl 2) Achievement rate of HbA1c <6.5% by sitagliptin treatment 3)Durability of vildagliptin or alogliptin	—

Countries

Japan

Contacts

Public ContactErina Shigematu

Yokohama City University Medical Center Department of Endocrinology and Diabetes

erina-sgmt@live.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026